Comparison of Effect of Nepafenac and Diclofenac Ophthalmic Solutions on Cornea, Tear Film, and Ocular Surface After Cataract Surgery: the Results of a Randomized Trial

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2016 Mar 29

PMID 27019091

Citations 6

Authors

Atsushi Kawahara

Tsugiaki Utsunomiya

Yuji Kato

Yoshinori Takayanagi

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to compare the effects of nepafenac ophthalmic suspension 0.1% (Nevanac) and diclofenac sodium ophthalmic solution 0.1% (Diclod) on the cornea, tear film, and ocular surface after cataract surgery.

Methods: A total of 60 eyes (60 patients) were selected for this study, with no ocular diseases other than cataract (scheduled for cataract surgery by one surgeon). Patients were randomly enrolled to receive nepafenac or diclofenac in the perioperative period, and cataract surgery was performed using torsional microcoaxial phacoemulsification and aspiration with intraocular lens implantation via a transconjunctival single-plane sclerocorneal incision at the 12 o'clock position. We compared intra- and intergroup differences preoperatively and postoperatively in conjunctival and corneal fluorescein staining scores, tear film breakup times, Schirmer's tests, the Dry Eye Related Quality of Life Scores, and tear meniscus areas using anterior segment optical coherence tomography.

Results: The diclofenac group had significantly higher conjunctival and corneal fluorescein staining scores at 4 weeks postoperatively compared with the nepafenac group (P<0.001). Within the diclofenac group, significantly higher conjunctival and corneal fluorescein staining scores were noted at 4 weeks postoperatively than those seen preoperatively (P<0.001) and at 1 week postoperatively (P<0.001). No statistically significant differences were found in any other items.

Conclusions: Nepafenac ophthalmic suspension 0.1% is considered safe for the corneal epithelium after cataract surgery.

Citing Articles

Topical NSAIDs impact on macular oedema and visual outcome after phacoemulsification: systematic review of RCTs with network meta-analysis.

Almasri M, Ismaiel A, Gavris I, Leucuta D, Gavris M, Nicoara S Eye (Lond). 2024; 38(17):3222-3230.

PMID: 39095467 PMC: 11584663. DOI: 10.1038/s41433-024-03268-x.

Intricate insights into immune response in dry eye disease.

Kaur R, Gurnani B, Kaur K Indian J Ophthalmol. 2023; 71(4):1248-1255.

PMID: 37026255 PMC: 10276682. DOI: 10.4103/IJO.IJO_481_23.

Current Advances in Mechanisms and Treatment of Dry Eye Disease: Toward Anti-inflammatory and Immunomodulatory Therapy and Traditional Chinese Medicine.

Ling J, Chan B, Tsang M, Gao X, Leung P, Lam C Front Med (Lausanne). 2022; 8:815075.

PMID: 35111787 PMC: 8801439. DOI: 10.3389/fmed.2021.815075.

In Vitro and Ex Vivo Evaluation of Nepafenac-Based Cyclodextrin Microparticles for Treatment of Eye Inflammation.

Lorenzo-Veiga B, Diaz-Rodriguez P, Alvarez-Lorenzo C, Loftsson T, Sigurdsson H Nanomaterials (Basel). 2020; 10(4).

PMID: 32283583 PMC: 7221994. DOI: 10.3390/nano10040709.

Evaluation of the Protective Effect of an Ophthalmic Viscosurgical Device on the Ocular Surface in Dry Eye Patients during Cataract Surgery.

Yoon D, Kim J, Jeon H, Jeon H, Han S, Hyon J Korean J Ophthalmol. 2019; 33(5):467-474.

PMID: 31612658 PMC: 6791951. DOI: 10.3341/kjo.2019.0060.

References

Cho Y, Kim M . Dry eye after cataract surgery and associated intraoperative risk factors. Korean J Ophthalmol. 2009; 23(2):65-73. PMC: 2694295. DOI: 10.3341/kjo.2009.23.2.65. View

Shimazaki J, Saito H, Yang H, Toda I, Fujishima H, Tsubota K . Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops. Cornea. 1995; 14(6):623-7. View

Li X, Hu L, Hu J, Wang W . Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery. Cornea. 2007; 26(9 Suppl 1):S16-20. DOI: 10.1097/ICO.0b013e31812f67ca. View

McGhee C, Dean S, Danesh-Meyer H . Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002; 25(1):33-55. DOI: 10.2165/00002018-200225010-00004. View

Lindstrom R . The pharmacologic and pathophysiologic rationale for using NSAIDs in ocular inflammatory disease and ocular surgery. Int Ophthalmol Clin. 2006; 46(4):7-11. DOI: 10.1097/01.iio.0000212131.98760.a9. View

Uyemura S, Santos A, Mingatto F, Jordani M, Curti C . Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch Biochem Biophys. 1997; 342(2):231-5. DOI: 10.1006/abbi.1997.9985. View

Sugai S, Yoshitomi F, Oshika T . Transconjunctival single-plane sclerocorneal incisions versus clear corneal incisions in cataract surgery. J Cataract Refract Surg. 2010; 36(9):1503-7. DOI: 10.1016/j.jcrs.2010.03.045. View

Walters T, Raizman M, Ernest P, Gayton J, Lehmann R . In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007; 33(9):1539-45. DOI: 10.1016/j.jcrs.2007.05.015. View

Baudouin C . Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol. 2005; 5(5):459-63. DOI: 10.1097/01.all.0000183112.86181.9e. View

10.

Kapin M, Yanni J, Brady M, McDonough T, Flanagan J, Rawji M . Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003; 27(5):281-91. DOI: 10.1023/a:1026024409826. View

11.

Hersh P, Rice B, Baer J, WELLS P, Lynch S, McGuigan L . Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 1990; 108(4):577-83. DOI: 10.1001/archopht.1990.01070060125062. View

12.

Assouline M, Renard G, Arne J, David T, Lasmolles C, Malecaze F . A prospective randomized trial of topical soluble 0.1% indomethacin versus 0.1% diclofenac versus placebo for the control of pain following excimer laser photorefractive keratectomy. Ophthalmic Surg Lasers. 1998; 29(5):365-74. View

13.

Sawazaki R, Ishihara T, Usui S, Hayashi E, Tahara K, Hoshino T . Diclofenac protects cultured human corneal epithelial cells against hyperosmolarity and ameliorates corneal surface damage in a rat model of dry eye. Invest Ophthalmol Vis Sci. 2014; 55(4):2547-56. DOI: 10.1167/iovs.13-13850. View

14.

Ayaki M, Yaguchi S, Iwasawa A, Koide R . Cytotoxicity of ophthalmic solutions with and without preservatives to human corneal endothelial cells, epithelial cells and conjunctival epithelial cells. Clin Exp Ophthalmol. 2008; 36(6):553-9. DOI: 10.1111/j.1442-9071.2008.01803.x. View

15.

Qu M, Wang Y, Yang L, Zhou Q . Different cellular effects of four anti-inflammatory eye drops on human corneal epithelial cells: independent in active components. Mol Vis. 2011; 17:3147-55. PMC: 3235539. View

16.

Gamache D, Graff G, Brady M, Spellman J, Yanni J . Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000; 24(4):357-70. DOI: 10.1023/a:1007049015148. View

17.

Ku E, Lee W, Kothari H, Scholer D . Effect of diclofenac sodium on the arachidonic acid cascade. Am J Med. 1986; 80(4B):18-23. DOI: 10.1016/0002-9343(86)90074-4. View

18.

Oh T, Jung Y, Chang D, Kim J, Kim H . Changes in the tear film and ocular surface after cataract surgery. Jpn J Ophthalmol. 2012; 56(2):113-8. DOI: 10.1007/s10384-012-0117-8. View

19.

Takahashi N, Miyakoshi M, Taka N, Kurihara T, Fujikawa K . [Cytotoxic effects of diclofenac sodium]. Nippon Ganka Gakkai Zasshi. 1993; 97(2):145-9. View

20.

Guidera A, Luchs J, Udell I . Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs. Ophthalmology. 2001; 108(5):936-44. DOI: 10.1016/s0161-6420(00)00538-8. View